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Abstract
Summarizing the status of drugs in the market and examining the trend of drug research and development is important in
drug discovery. In this study, we compared the drug targets and the market sales of the new molecular entities approved by
the U.S. Food and Drug Administration from January 2000 to December 2009. Two networks, namely, the target–target and
drug–drug networks, have been set up using the network analysis tools. The multi-target drugs have much more potential,
as shown by the network visualization and the market trends. We discussed the possible reasons and proposed the rational
strategies for drug research and development in the future.
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Introduction
Despite the considerable progress in the high-throughput
screening method, the rational drug design, and the massive
drug-development efforts, the number of successful drugs did not
significantly increase during the past decade [1]. The strategy for
screening single-target and highly specific agents was widely
researched for some time [2,3]. However, this effort has not been
very successful, and undeniably, the bottleneck lies in the area of
drug research and development [2]. Until now, there are still not
fully effective drugs for treating complex diseases, such as cancer,
metabolic diseases, cardiovascular diseases, and neurological
diseases. Thus, we believe that the strategy or models used for
new drug discovery have to be reconsidered.
Recent developments in biological systems and overall clinical
experience have revealed that the single-target drugs may not
always induce the desired effect to the entire biological system
even if they successfully inhibit or activate a specific target [1,2,4],
one reason is that organisms can affect effectiveness through
compensatory ways. The development of diseases, particularly the
complex ones, involves several aspects. Thus, scientists have
recently proposed the multi-target drug design concept [1,4,5].
This manuscript aims to determine the status of drug research and
development through network views and market sales in the past
decade and confirm whether multi-target drugs are the current
trend in drug research and development. We also propose rational
strategies for future drug research and development.
Results
Drug Targets
The total number of sampled new molecular entities (NMEs)
approved by the U.S. Food and Drug Administration (FDA) from
January 2000 to December 2009 has reached 223. The average
target number of sampled drugs is 2.5, which is higher than the 1.8
reported by Yildirim et al. using Drugbank data before March
2006 [6,7]. This increase may partly indicate the rising targets per
drug in the recent years.
Target–target Network
The target–target (Figure 1) and drug–drug (Figure 2) networks
were built as described in the Materials and Methods section to
make a realistic visualization of information and directly determine
the connections between targets and drugs, thereby providing
important information on the current status of drug discovery.
The targets of the anti-cancer drugs, anti-infection drugs and
anti-nervous-system-related -diseases agents, among others, have
been effectively separated to some extent (Figure 1). For example,
most of the targets for cancer therapy, such as different types of
tyrosine kinase, were clustered in the left panel, whereas most of
the nervous-system-related targets, such as dopamine receptors,
5-hydroxytryptamine receptor, adrenergic receptors, and hista-
mine receptors, among others, were clustered on the right. The
targets for cancer treatment were relatively more scattered than
those for other diseases, indicating the complex mechanism
involved in cancer development and the diverse methods for
cancer chemotherapy.
Most of the targets have connections with the others (at least with
one drug) through target–target network visualization, which
further confirms the importance of multi-target drugs. Although
some drugs were developed based on the single-target strategy,
researchers later discovered the diversity of their targets. Their lines
were thicker than the others, indicating that more drugs affect these
targets. A typical aggregation is that of tyrosin kinases. In fact,
several anti-cancer drugs target MCSF1R (macrophage colony-
stimulating factor 1 receptor), MSCGFR (mast/stem cell growth
factor receptor), POTPKABL1 (proto-oncogene tyrosine-protein
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receptor 2), among others. This development exhibits the recent
trend of anti-cancer drug discovery. Another remarkable aggrega-
tion includes 5H1BR (5-hydroxytryptamine 1B receptor), 5H1DR
(5-hydroxytryptamine 1D receptor), 5H2AR (5-hydroxytryptamine
2A receptor), D2DR [D(2) dopamine receptor], D3DR [D(3)
dopamine receptor], D4DR [D(4) dopamine receptor], HH1R
(histamine H1 receptor), and so on. These receptors are the targets
for the treatment of nervous system diseases. These observations
also indicate the market demand in the recent years.
We also conducted a centrality analysis and found that
ABCSGM2 (ATP-binding cassette sub-family G member 2),
Figure 1. Target–target network. The circles indicate the targets and the size of circles represents nodal degree. The links between the targets
represent the number of drugs simultaneously focused by two neighboring targets. Thicker ties mean stronger interactions, whereas thinner links
represent weaker relationships.
doi:10.1371/journal.pone.0040262.g001
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hydroxylase), MRP1 (multi-drug resistance protein 1), A1AAR
(Alpha-1A adrenergic receptor), B1AR (Beta-1 adrenergic
receptor), among others, present relative high betweenness centrality
in the target–target network (Table 1), indicating their importance in
this network and the potential of development of new drugs.
Figure 2. Drug–drug network. The circles indicate the drugs and the size of circles represents nodal degree. The circles of nodes without any line
will disappear in the networks because their nodal degree is equal to zero. The links between the drugs represent the number of targets
simultaneously focused by the two neighboring drugs. Thicker ties mean stronger interactions, whereas thinner links represent weaker relationships.
Red, alimentary tract and metabolism; Yellow, nervous system; Blue, general anti-infectives systemic; Green, antineoplastic and immunomodulating
agents; Purple, genito-urinary system and sex hormones; Grey, respiratory system; Black, cardiovascular system; White, others.
doi:10.1371/journal.pone.0040262.g002
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Drugs used in treating the similar disease do not significantly
accumulate (Figure 2), and only drugs that target dopamine
receptors, 5-hydroxytryptamine receptor, adrenergic receptors,
and histamine receptors for the treatment of neurological diseases
etc. cluster relatively closer compared with the others (Figure 2).
This phenomenon may be attributed to a variety of targets for the
same disease and is significantly evident in anti-cancer drugs. For
example, DNA, DNA synthesis-related enzymes, different types of
tyrosine kinases, histone deacetylase inhibitors, and proteasome
inhibitors, among others, are all anti-cancer targets, which lead to
the development of anti-drugs in different clusters. In particular,
ARRANON, DACOGEN, ELOXATIN, and VIDAZA target
DNA; TARCEVA, TYKEERB, and IRESSA target EGFR
(epidermal growth factor receptor); NEXAVAR, SUTENT,
GLEEVEC, and SPRYCEL target other tyrosine kinases;
ZOLINZA targets histone deacetylases; and VELCADE targets
proteasome. Therefore, the aforementioned drugs are not
clustered together although all of them are used in treating cancer.
Interestingly, TRISENOX is linked to other tyrosine kinase
inhibitors, indicating its tyrosine kinase inhibitory activity.
Moreover, no drug that simultaneously inhibits EGFR and other
tyrosine kinases has been discovered, hence the need for further
studies. Several drugs, such as FUZEON, JANUVIA, and
XIFAXAN, among others, are not correlated with any other
drugs, indicating that they have no common targets with other
drugs or the correlation between these targets and the known ones
is not yet clear.
Product Sales
Some preliminary associations between pharmaceutical targets
and sales have been identified in our past research [7]. For
example, pharmaceutical sales is positively correlated to the
number of drug targets, while the average number of targets of
blockbuster drugs seems to be higher than one of common drugs
[7]. These results do not, however, indicate the essential cor-
relation between pharmaceutical targets and business value in view
of the complex interactive relationship between drugs and targets.
A new indicator popularly used in network analysis, betweenness
centrality, is further employed in this research. The betweenness
centrality of the sampled drug in the drug–drug network and its
product sales (Pearson’s correlation coefficient =0.371, P,0.001)
have significant correlation, which further revealing the associa-
tion between the targets’ bridging effect on drugs and economic
value. A drug with high betweenness centrality is often a multi-
target drug representing an important mediator in the interaction
among different targeted therapeutic drugs. This kind of drugs
highly shares and controls certain important targeted conduction
pathways for the disease therapies of other drugs and thus has a
high probability of becoming a best-selling drug.
Discussion
In this paper, two networks, namely, the target–target and
drug–drug networks (Figure 1 and Figure 2), were visualized using
network analysis tools. The drug discovery status and trend were
analyzed based on the new NMEs approved by the U.S. FDA
from January 2000 to December 2009.
The average target number of sampled drugs from January
2000 to December 2009 is slightly higher than that of the drugs
collected by Drugbank before May 2006 [6,7]. Moreover, the
average target number of blockbuster drugs is also higher than that
of all our collected samples [7]. These observations indicate that
multi-target drug discovery is indeed a status over the past decade
and a possible trend in the future, although many single-target
drugs are still used today. This development is primarily due to the
Table 1. Top 20 betweenness centrality in the target–target network.
Rank Targets Abbreviation Targets Full Name Betweenness Centrality
1 ABCSGM2 ATP-binding cassette sub-family G member 2 0.0395048
2 NOSE Nitric-oxide synthase, endothelial 0.0390933
3 P4H Phenylalanine-4-hydroxylase 0.0379617
4 MRP1 Multi-drug resistance protein 1 0.0255478
5 A1AAR Alpha-1A adrenergic receptor 0.0247959
6 B1AR Beta-1 adrenergic receptor 0.0131237
7 BPDGFR Beta platelet-derived growth factor receptor 0.0089909
8 MSCGFR Beta platelet-derived growth factor receptor 0.0089909
9 5H1AR 5-hydroxytryptamine 1A receptor 0.0047314
10 5H1DR 5-hydroxytryptamine 1D receptor 0.0047314
11 H1P HIV-1 protease 0.0045266
12 POTPKABL1 Proto-oncogene tyrosine-protein kinase ABL1 0.0041608
13 5H7R 5-hydroxytryptamine 7 receptor 0.0026662
14 APDGFR Alpha platelet-derived growth factor receptor 0.0021861
15 MCSF1R Macrophage colony-stimulating factor 1 receptor 0.0021861
16 D4DR D(4) dopamine receptor 0.0021604
17 D3DR D(3) dopamine receptor 0.0021604
18 D2DR D(2) dopamine receptor 0.0021604
19 SDDT Sodium-dependent dopamine transporter 0.0021565
20 SDST Sodium-dependent serotonin transporter 0.0006687
doi:10.1371/journal.pone.0040262.t001
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alteration in the market share of therapeutic areas. The sales of
drugs for nervous and cardiovascular system diseases and anti-
neoplastic agents exceed the average sales of all drugs [7]. In fact,
cancer and those nervous and cardiovascular system diseases are
complicated, thereby promoting the multi-targeted therapies as a
better pathway to achieve the desired treatment. For example, the
therapeutic targets for cancer include tubulin, topoisomerases,
various types of tyrosine kinases, mammalian target of rapamycin,
phosphatidylinositol 3-kinase, histone deacetylases, focal adhesion
kinase, AMP-activated protein kinase (AMPK), 26S proteasome
complex, and cyclooxygenase, among others [8,9,10,11,12,13,14,
15,16,17,18]; the therapeutic targets for Alzheimer’s disease
include acetylcholinesterase, secretase, monoamine oxidase B,
and t protein, among others [19,20,21,22,23]; the therapeutic
targets for atherosclerosis include acylcoenzyme A-cholesterol
acyltransferase, high density lipoprotein, lectin like oxidized low
density lipoprotein receptor, AMPK, and peroxisome proliferator-
activated receptor (PPAR), among others [18,24,25,26,27]. It
seems that using single-targeted agents to cure these complex
diseases is almost impossible. The multiple tyrosine kinase
inhibitor imatinib induces better anti-cancer effects compared
with that of gefitinib, which involves a single target [28], further
indicating that drugs with multiple targets may exhibit a better
chance of affecting the complex equilibrium of whole cellular
networks than drugs that act on a single target. Actually, there are
several molecular targets, such as dopamine receptors, 5-
hydroxytryptamine receptor, adrenergic receptors, cyclooxygen-
ase, monoamine oxidase B, AMPK, PPAR, etc. (Fig. 1 and
[12,18,26,29,30,31]), are common to the complex human diseases,
indicts that these targets may play vital roles in the development of
complex disease and also suggests that drugs target these targets
may have the potential for the secondary development.
Then, how do we develop multi-targeted drugs successfully?
Although a number of marketed drugs are thought to derive their
therapeutic benefit by interacting with multiple targets, majority of
these were discovered accidentally. Therefore, the rational
discovery of multi-target drugs is an emerging area. For instance,
tyrosine kinases are good targets for the treatment of cancer, and
several drugs have already been approved by the U.S. FDA. As
targeting several tyrosine kinase receptors at once may dramat-
ically affect the progression of cancer and decrease resistance,
some multi-target tyrosine kinase inhibitors have been developed
in the recent years [14,15,32]. Though there are some studies for
multi-target drug design in the recent years [19,20,33], it is still a
long way to rationally design promising multi-target agents based
on current knowledge. The most important thing is that we still
not clear which targets should be combined to design better drugs
for the specific complex diseases. As natural products are a rich
reservoir for drug discovery because of their diversity and
complexity structures [34,35] and most of the natural products
are multi-target, we propose that screening the new compounds
from natural products based on high content screening is an
effective strategy. It is also worthy to re-screening and re-
evaluating the dirty compounds such as curcumin [36,37,38,
39,40], berberine [37,38,41], and baicalein [42], among others. Of
course it is worth noting that there are also several disadvantages
of natural products, such as low bioavailability, weak effects, and
complex molecular mechanism of actions, among others [34].
Thus, structure modification using medicinal chemistry and
pharmaceutical technologies and mechanisms identification using
advanced modern technologies are necessary [35].
Combinatorial therapy is another kind of multi-target drug. The
treatment of cancer in clinical is almost combination therapy and
it is also increasingly used in the prevention and treatment of
AIDS, cerebral ischemia, Parkinson’s disease, and Alzheimer’s
disease, among others [43,44,45,46]. What will happen if all
known targets for one complex disease were simultaneously
affected using one compound or drug combination? Identifying
such compound or combination is actually impossible, and toxicity
is another problem that will be raised. Thus, one better way is to
combine the targets selectively according to the developing
knowledge and screen the compounds for rational drug discovery.
Therefore, the mechanisms causing a particular disease must be
clarified. The rapid development of technologies in biological
systems such as genomics, proteomics, metabonomics and so on,
may enhance our understanding of the nature of the disease,
effectively find possible therapeutic targets, and generate computer
models that will identify the correct multi-fitting and further make
this novel drug design paradigm successful.
In summary, we applied network analysis tools and successfully
visualized the information. The approach may still have more or
less biases. For example, some targets information may be changed
due to the growth of knowledge. Nevertheless, we have confirmed
the status of drug discovery in the recent years and put forward the
possible future trend.
Materials and Methods
Data Sources
All NMEs approved by the U.S. FDA from January 2000 to
December 2009 were taken from the Drugs@FDA database. The
targets of all sample drugs were individually collected from the
Drugbank database in 2011, while the drug–target pairs were
constructed accordingly. Furthermore, the therapeutic classifica-
tion and sales information of the sample drugs were collected from
the IMS Health database, a leading pharmaceutical market
database in the world, using all NMEs’ brand names as retrieval
keywords.
Network Construction
The drug–target pairs were visualized based on the interaction
between the drugs and targets using network analysis tools (Pajek and
NetDraw). The original two-mode drug–target network was further
constructed, wherein two types of nodes, namely, drugs and targets,
and edges represent the strength of interaction between drugs and
targets, which is measured by the frequency of their interactions.
Thicker ties mean stronger interactions, whereas thinner links
represent weaker relationships. Moreover, the two-mode drug–target
network was converted into one-mode drug–drug and target–target
networks based on the network neighborhood. The drug–drug
network only includes drugs as network members, whereas the ties
betweendrugs represent the number of targets simultaneously focused
by two neighboring drugs. On the contrary, a target–target network is
composed of only target members, their links stand represent the
number of drugs that focus on the two neighboring targets.
Centrality Analysis
Centrality measures the location of network nodes. Betweenness
centrality indicates the interval between one node and the other
nodes, demonstrating the medium degree of a certain node within
the network
Cb~
X
jvk
gjk(ni)=gjk
where gjk denotes the geodesic number between node j and node k
and gjk(ni) indicates the geodesic number involving node ni between
The Trend of Drug R&D
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The betweenness centrality ranges from 0 to 1:0 means that the
node cannot control any other nodes in the network, whereas 1
indicates that the node seizing the central position in the network
can entirely control all other nodes. Herein, the betweenness
centrality of nodes in drug and target networks was measured
accordingly, and the importance and role of specific drugs and
targets in the networks were observed.
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